

Item 5.07 Submission of Matters to a Vote of Security Holders.

On April 26, 2019, Cellular Biomedicine Group, Inc. (the “Company”) completed its 2019 annual meeting of stockholders (the “Annual Meeting”). The number of shares of common stock entitled to vote at the Annual Meeting was 18,089,504 shares. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 14,194,659 shares. All matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved, and Terry Belmont and Hansheng Zhou were elected “Class I” directors.

The following is a tabulation of the voting on the proposals presented at the Annual Meeting:

(i) To elect two (2) “Class I” directors, Terry Belmont and Hansheng Zhou, each of whom will be elected for a term of three years, or until the election and qualification of their successors.

Nominee	Shares Voted For	Shares Withheld	Broker Non-Vote
Terry Belmont	13,307,033	886,502	1,124
Hansheng Zhou	13,898,378	295,157	1,124

(ii) To ratify the appointment of BDO China Shu Lun Pan Certified Public Accountants LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.

Shares Voted For	Shares Voted Against	Shares Abstaining	Broker Non-Vote
14,188,846	5,810	3	1,124

(iii) To approve the Company’s 2019 Equity Incentive Plan with 1,500,000 shares initially available for issuance.

Shares Voted For	Shares Voted Against	Shares Abstaining	Broker Non-Vote
14,188,846	5,810	3	1,124

Item 7.01 Regulation FD Disclosure.

On April 29, 2019, the Company issued a press release announcing the results of the Annual Meeting. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release, dated April 29, 2019

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group,
Inc.

Date: April 29, 2019 By: /s/ Bizuo (Tony) Liu
Bizuo (Tony) Liu
Chief Executive Officer